VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
CSTL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
CSTLCastle Biosciences, Inc.
$32.52$986M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksCSTLEarnings History

CSTL logoCastle Biosciences, Inc. (CSTL) Earnings History

Net Loss

9 years of earnings data (2017–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$23M
● Net Loss
TTM EPS (Diluted)
$-0.75
Per share, diluted
YoY EPS Growth
-233.9%
Declining
Net Margin
-7.0%
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating Margin-12.4%
Gross Margin79.4%
Return on Equity-5.2%
Return on Assets-4.4%
Record Annual Net Income$18MFY2024
Record Quarterly EPS$0.36Q4 2018
Consecutive Profitable Years0years
Q3 2026
Net Income-$4M
EPS (Diluted)$-0.13
YoY Growth-233.9%Declining
QoQ Growth-99.0%Declining

Loading earnings history...

Castle Biosciences, Inc. (CSTL) Earnings Overview

As of November 8, 2026, Castle Biosciences, Inc. (CSTL) reported trailing twelve-month net income of -$23M, reflecting -233.9% year-over-year growth. The company earned $-0.75 per diluted share over the past four quarters, with a net profit margin of -7.0%.

Looking at the long-term picture, CSTL's historical earnings data spans multiple years. The company achieved its highest annual net income of $18M in fiscal 2024.

Castle Biosciences, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including NTRA (-$165M net income, -9.0% margin), VCYT ($127M net income, 12.8% margin), ARDX (-$55M net income, -15.1% margin), CSTL has outperformed on profitability metrics. Compare CSTL vs NTRA →

CSTL Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
CSTL logoCSTLCurrent
-$23M$-0.75-7.0%-5.2%-233.9%—
NTRA logoNTRA
-$165M$-1.14-9.0%-14.3%+0.7%
VCYT logoVCYT
$127M$1.5312.8%5.3%+164.5%
ARDX logoARDX
-$55M$-0.22-15.1%-36.2%-52.9%
FLGT logoFLGT
-$91M$-3.29-18.8%-5.4%-39.7%
GH logoGH
-$485M$-3.61-42.4%-+6.7%
Best in group
Lowest in group

CSTL Historical Earnings Data (2017–2025)

9 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025-$24M-232.4%-$43M$-0.83-7.0%-12.4%
2024$18M+131.7%$9M$0.625.5%2.6%
2023-$57M+14.4%-$68M$-2.14-26.1%-30.9%
2022-$67M-114.6%-$73M$-2.58-49.0%-53.2%
2021-$31M-204.3%-$40M$-1.24-33.3%-42.6%
2020-$10M-294.9%-$7M$-0.54-16.4%-10.4%
2019$5M+182.9%$7M$-0.2110.2%14.1%
2018-$6M+48.5%-$4M$-0.60-27.9%-16.8%
2017-$12M--$11M$-1.26-89.9%-79.2%

Download Data

Export CSTL earnings history in CSV or JSON format

Free sign-in required to download data

Consensus & Technical Research Suite
Open CSTL Terminal

CSTL Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

9+ years return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

CSTL — Frequently Asked Questions

Quick answers to the most common questions about buying CSTL stock.

What is CSTL earnings per share (EPS)?

CSTL trailing twelve-month (TTM) diluted EPS is $-0.75, reflecting -233.9% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2017 to 2025 is available in the table on this page.

What is Castle Biosciences, Inc.'s net income?

Castle Biosciences, Inc. (CSTL) trailing twelve-month net income is $-23M as of 2025. Earnings declined -233.9% year-over-year.

Is CSTL profitable?

CSTL is not currently profitable on a TTM basis, reporting a net loss of $-23M. Net margin is -7.0%. Investors should monitor for a return to profitability.

What is CSTL's earnings growth rate?

CSTL compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2017 to 2025.

What are CSTL's profit margins?

Castle Biosciences, Inc. net profit margin is -7.0%, operating margin is -12.4%, and gross margin is +79.4%. Below-average margins reflect competitive or cost pressures. Return on Equity is -5.2%.

Is CSTL growing earnings?

CSTL earnings are declining — EPS fell -233.9% year-over-year. TTM net income dropped to $-23M. This contrasts with the 5-year CAGR of N/A.

What was CSTL's best earnings year?

Castle Biosciences, Inc.'s highest annual net income on record is $18M, achieved in fiscal year 2024. Earnings history on this page spans 2017 to 2025 and includes all annual and quarterly figures.

What were CSTL's earnings last quarter?

CSTL's most recent reported quarter was Q3 2026. Net income was $-4M with diluted EPS of $-0.13. For a full breakdown of all quarters, see the quarterly earnings table on this page.

CSTL Earnings Over Time (2017–2025)

Net income & EPS — annual and quarterly view